# Silibin A

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/silibin-a
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-03-28
**Evidence Score:** 2 / 10
**Category:** Compound
**Also Known As:** Silybin A, Silibin A, Silybin diastereomer A, Milk thistle flavonolignan A, Silymarin component A, (2R,3R)-Silybin

## Overview

Silibinin A is a flavonolignan compound found in milk thistle that exhibits [hepatoprotective](/ingredients/condition/detox) properties through antioxidant mechanisms and modulation of cellular signaling pathways. This bioactive compound demonstrates liver protection by inhibiting [oxidative stress](/ingredients/condition/antioxidant) and supporting cellular membrane stability.

## Health Benefits

• Potential [hepatoprotective](/ingredients/condition/detox) effects against toxins as indicated by in vitro and animal studies. • [Antioxidant](/ingredients/condition/antioxidant) properties due to its flavonolignan structure, supporting cellular protection. • Inhibition of bile acid transporters SLCO1B1 and SLCO2B1, which may affect bile acid [metabolism](/ingredients/condition/weight-management). • Part of silymarin, traditionally used for liver support in Western herbal medicine. • Limited direct evidence on human health benefits, with most research focusing on silibinin or silymarin as a whole.

## Mechanism of Action

Silibinin A exerts [hepatoprotective](/ingredients/condition/detox) effects by stabilizing hepatocyte cell membranes and reducing [lipid peroxidation](/ingredients/condition/antioxidant) through its phenolic hydroxyl groups. The compound inhibits bile acid transporters SLCO1B1 and SLCO2B1, affecting hepatic bile acid uptake and [metabolism](/ingredients/condition/weight-management). Additionally, it modulates inflammatory pathways by reducing [pro-inflammatory cytokine](/ingredients/condition/inflammation) production and supporting cellular antioxidant defense systems.

## Clinical Summary

Current evidence for silibinin A is primarily derived from in vitro cell culture studies and animal models investigating liver protection mechanisms. Laboratory studies demonstrate significant [hepatoprotective](/ingredients/condition/detox) effects against various toxins, with some showing 40-60% reduction in liver damage markers. Human clinical data specifically for silibinin A as an isolated compound remains limited, with most clinical research focusing on silymarin complex containing multiple flavonolignans. The existing preclinical evidence suggests promising hepatoprotective potential, but controlled human trials are needed to establish clinical efficacy and optimal dosing.

## Nutritional Profile

Silibin A is not a nutrient or food but a specific flavonolignan compound (molecular formula C₂₅H₂₂O₁₀, molecular weight ~482.44 g/mol) and one of the two diastereomers of silybin, the principal bioactive component of silymarin extracted from milk thistle (Silybum marianum) seeds. It contains no macronutrients (protein, fat, carbohydrates) or appreciable vitamins/minerals in its pure form. Key bioactive characteristics: • Flavonolignan structure consisting of a taxifolin (dihydroquercetin) moiety linked to a coniferyl alcohol unit via an oxeran ring. • Silibin A is the 2R,3R,10R,11R diastereomer, distinguishable from Silibin B (2R,3R,10S,11S) by stereochemistry at C-10 and C-11. • Typically constitutes approximately 15–25% of crude silymarin extract alongside silibin B, isosilibinin A/B, silychristin, and silydianin. • In silymarin-standardized milk thistle extracts (typically 70–80% silymarin), silibin A and B together represent roughly 40–60% of total flavonolignans. • Possesses multiple phenolic hydroxyl groups (positions 3, 5, 7, and 20) contributing to [antioxidant](/ingredients/condition/antioxidant) radical-scavenging capacity. • Oral bioavailability is notably poor (~0.73–0.95% in some pharmacokinetic studies) due to low aqueous solubility (~0.04 mg/mL), rapid phase II [metabolism](/ingredients/condition/weight-management) (extensive glucuronidation and sulfation in the gut wall and liver), and significant biliary excretion. • Plasma half-life is approximately 1–3 hours in humans after oral dosing. • Bioavailability can be enhanced 4–10 fold through phospholipid complexation (phytosome formulations, e.g., silybin-phosphatidylcholine complex), micronization, or co-administration with solubilizing agents. • Primary metabolites include silibin A-20-O-β-D-glucuronide and silibin A-7-O-sulfate, formed via UGT1A1, UGT2B7, and SULT2A1 enzymes. • No significant caloric contribution; used exclusively as a bioactive/pharmacological agent rather than a nutritional supplement in the conventional sense.

## Dosage & Preparation

No clinically studied dosage ranges for silybin A alone are specified. Standardized silymarin extracts contain 50–70% silybin (A+B). Consult a healthcare provider before starting any new supplement.

## Safety & Drug Interactions

Silibinin A appears to have a favorable safety profile based on animal studies, with no significant acute toxicity reported at standard doses. The compound may interact with medications metabolized through bile acid transporters, particularly those substrates of SLCO1B1 and SLCO2B1. Potential interactions could occur with statins, certain antibiotics, and other hepatically-metabolized drugs due to its effects on liver transport systems. Safety data during pregnancy and lactation is insufficient, and individuals with gallbladder disease should exercise caution due to potential effects on bile acid [metabolism](/ingredients/condition/weight-management).

## Scientific Research

There is a lack of specific human clinical trials, RCTs, or meta-analyses focusing solely on silybin A. Most available evidence pertains to silibinin or silymarin in general, with no individual PMIDs provided for silybin A.

## Historical & Cultural Context

While silybin A itself does not have detailed historical uses, silymarin from milk thistle has been used in Western herbal traditions primarily for liver support. Specific traditional uses of silybin A are not documented.

## Synergistic Combinations

Milk thistle extract, Vitamin E, Curcumin, Quercetin, N-acetylcysteine

## Frequently Asked Questions

### What is the difference between silibinin A and silymarin?

Silibinin A is a single flavonolignan compound, while silymarin is a complex mixture containing silibinin A, silibinin B, silychristin, and silydianin extracted from milk thistle. Silymarin typically contains 50-70% silibinin compounds, with silibinin A being one of the major active components.

### How much silibinin A is needed for liver protection?

Specific dosing for isolated silibinin A has not been established in human studies. Most research uses silymarin extracts containing 100-400mg daily of total silibinin compounds. Individual silibinin A requirements would likely be lower since it represents only a portion of the total silibinin content.

### Can silibinin A help with fatty liver disease?

Preclinical studies suggest silibinin A may support liver health through antioxidant and anti-inflammatory mechanisms relevant to fatty liver conditions. However, human clinical trials specifically testing silibinin A alone for fatty liver disease are lacking, and most evidence comes from silymarin complex studies.

### Does silibinin A affect cholesterol levels?

Silibinin A may indirectly influence cholesterol metabolism through its inhibition of bile acid transporters SLCO1B1 and SLCO2B1, which are involved in bile acid recycling. However, direct effects on cholesterol synthesis or specific cholesterol-lowering benefits have not been definitively established in human studies.

### How long does silibinin A stay in the body?

Silibinin compounds generally have poor oral bioavailability and are rapidly metabolized by the liver. Most silibinin is eliminated within 24-48 hours through hepatic conjugation and biliary excretion, though specific pharmacokinetic data for silibinin A alone is limited.

### Does silibinin A interact with common medications?

Silibinin A may interact with medications that are substrates of the bile acid transporters SLCO1B1 and SLCO2B1, potentially affecting their absorption and efficacy. This includes certain statins, antiretrovirals, and other drugs dependent on these transport pathways. Anyone taking prescription medications should consult a healthcare provider before adding silibinin A supplements to avoid potential interactions.

### What is the most bioavailable form of silibinin A?

Silibinin A has relatively poor bioavailability when taken orally due to limited absorption and rapid metabolism. Phospholipid complexes and phytosome formulations of silymarin (which contains silibinin A) have been developed to enhance absorption, though direct comparisons specific to isolated silibinin A are limited. Standardized silymarin extracts remain the most commonly studied and used form in research.

### Who should avoid silibinin A supplementation?

Pregnant and breastfeeding women should avoid silibinin A due to insufficient safety data in these populations. Individuals with allergies to plants in the Asteraceae family (ragweed, chrysanthemums, daisies) may experience cross-reactivity since milk thistle is botanically related. Those taking medications metabolized by SLCO transporters should also consult a healthcare provider before use.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*